Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis

doi:10.3748/wjg.v21.i19.6044

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9103)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-9) series, Tables (1-2) series.

Item

Count

PDF

605

WORD

335

HTML

3892

Figures (1-9)

218

Tables (1-2)

236

Sum=5286

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1481

Download

2336

Sum=3817

May 21, 2015 (publication date) through Feb 8, 2025

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastroenterol. May 21, 2015; 21(19): 6044-6051
Published online May 21, 2015. doi: 10.3748/wjg.v21.i19.6044

Full Size Figure Download Figure

Figure 1 Flow diagram of the study selection.

Citation: Mei WQ, Hu HZ, Liu Y, Li ZC, Wang WG. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis. World J Gastroenterol 2015; 21(19): 6044-6051
URL: https://www.wjgnet.com/1007-9327/full/v21/i19/6044.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i19.6044